CEPH individuals are representative of the European American population: Implications for pharmacogenetics

Pharmacogenomics

Volumn 6, Issue 1, 2005, Pages 59-63

  Meucci, Melissa A ^a   Marsh, Sharon ^a   Watters, James W ^a   McLeod, Howard L ^a  

^a USA   (United States)

Author keywords

Allele frequency; CEPH; Genotype frequency; Pharmacogenetics; SNP

Indexed keywords

AFRICA; ARTICLE; BLOOD DONOR; DNA POLYMORPHISM; EUROPEAN AMERICAN; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; GERM LINE; HUMAN; PEDIGREE; PHARMACOGENETICS; POPULATION GENETICS; PREDICTION; STATISTICAL SIGNIFICANCE;

AFRICAN CONTINENTAL ANCESTRY GROUP; CELL LINE, TRANSFORMED; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENOTYPE; HUMANS; PEDIGREE; PHARMACOGENETICS; VARIATION (GENETICS);

EID: 13544267711     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.6.1.59     Document Type: Article

References (16)

1. Evans WE, McLeod HL: Pharmacogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med. 348, 538-549 (2003).
2. Dolan ME, Newbold KG, Nagasubramanian R et al.: Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res. 64, 4353-4356 (2004).
3. Watters JW. Kraja A, Meucci MA, Province MA, McLeod HL: Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc. Natl Acad. Sci. USA 101, 11809-11814 (2004).
4. Dausset J, Cann H, Cohen D, Lathrop M, Lalouel JM, White R: Centre d'etude du polymorphisme humain (CEPH): collaborative genetic mapping of the human genome. Genomics 6, 575-577 (1990).
5. Savage SA, Chanock SJ: Using germ-line genetic variation to investigate and treat cancer. Drug Discov. Today 9, 610-618 (2004 ).
6. Morley M, Molony CM, Weber TM et al.: Genetic analysis of genome-wide variation in human gene expression. Nature 430, 743-747 (2004).
7. Jen KY, Cheung VG: Transcriptional response of lymphoblastoid cells to ionizing radiation. Genome Res. 13, 2092-2100 (2003).
8. Yan H, Yuan W, Velculescu VE, Vogelstein B, Kinzler KW: Allelic variation in human gene expression. Science 297, 1143 (2002).
9. Cheung VG, Conlin LK, Weber TM et al.: Natural variation in human gene expression assessed in lymphoblastoid cells. Nat. Genet. 33, 422-425 (2003).
10. Schork NJ, Gardner JP, Zhang L et al.: Genomic association/linkage of sodium lithium countertransport in CEPH pedigrees. Hypertension 40, 619-628 (2002).
11. McLeod HL, Syvanen AC, Githang'a J et al.: Ethnic differences in catechol O-methyltransferase pharmacogenetics: frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or South-west Asian individuals. Pharmacogenetics 8, 195-199 (1998).
12. Ameyaw MM, Collie-Duguid ES, Powrie RH, Ofori-Adjei D, McLeod HL: Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum. Mol. Genet. 8, 367-370 (1999).
13. Marsh S, Kwok P, McLeod HL: SNP databases and pharmacogenetics: great start, but a long way to go. Hum. Mutat. 20, 174-179 (2002).
14. Marsh S, Collie-Duguid ES, Li T, Liu X, McLeod HL: Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 58, 310-312 (1999).
15. Rose CM, Marsh S, Ameyaw MM, McLeod HL: Pharmacogenetic analysis of clinically relevant genetic polymorphisms. Methods Mol, Med. 85, 225-237 (2003).
16. den Dunnen JT, Antonarakis SE: Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum. Mutat. 15, 7-12 (2000).